EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

The effect of aspirin on the risk of preeclampsia based on the Fetal Medicine Foundation first-trimester risk

Emmanuel Bujold, Daniel L Rolnik, Liona Poon, Argyro Syngelaki, David Wright, Kypros H Nicolaides

American Journal of Obstetrics and Gynecology · 2026-03 · 234 (3) · 770-778

DOI: 10.1016/j.ajog.2025.10.032 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Obstetrics and Gynecology, 2026-03. Verfasst von Emmanuel Bujold und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire de Québec-Laval University, Quebec City, Canada. Elect…. Hauptthemen laut MEDLINE: Aspirin, Pre-Eclampsia, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Seventh Framework Programme, Fetal Medicine Foundation, Quebec Health Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Aspirin reduces the risk of delivery with preterm preeclampsia among high-risk women, and such risk can be estimated in the first trimester of pregnancy using the Fetal Medicine Foundation algorithm by combining maternal factors with mean arterial pressure, uterine artery pulsatility index, and serum placental growth factor. It is unclear whether the initial risk influences the effect of aspirin. OBJECTIVE: This study aimed to estimate the effect of aspirin on preeclampsia according to first-trimester risk. STUDY DESIGN: This was a post hoc secondary analysis of the Aspirin for Evidence-Based Preeclampsia Prevention trial, which randomized participants with a first-trimester risk of preeclampsia with delivery before 37 weeks of gestation (preterm preeclampsia) of ≥1 in 100 (or 1%), based on the Fetal Medicine Foundation algorithm, to receive aspirin 150 mg or placebo daily from 11 to 14 weeks to 36 weeks of gestation. The rates of preeclampsia, preterm preeclampsia, and early preeclampsia (with delivery before 34 weeks of gestation) were calculated according to the initial Fetal Medicine Foundation risk. Among participants with high compliance (≥90% of tablets prescribed) based on regular tablet counts, the effect of aspirin was estimated according to the initial Fetal Medicine Foundation risk. Relative risks with 95% confidence intervals were calculated. RESULTS: Of 822 participants in the placebo group, those with an initial Fetal Medicine Foundation risk of ≥1 in 20 (or >5%) had an overall rate of preeclampsia (21.7%), preterm preeclampsia (8.4%), and early preeclampsia (6.4%) significantly greater than those with an initial risk of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AspirinPre-EclampsiaPlatelet Aggregation InhibitorsHumansFemalePregnancyPregnancy Trimester, FirstAdultPlacenta Growth FactorRisk AssessmentUterine ArteryPulsatile Flow

Stichwörter der Autor:innen

Aspirin for Evidence-Based Preeclampsia Prevention trialFetal Medicine Foundationaspirinbirthblood pressurefemalefirst trimestermean arterial pressureplacentaplacental growth factorpreeclampsiapregnancypreterm deliverypreterm preeclampsiaprevention

Substanzen

AspirinPlatelet Aggregation InhibitorsPlacenta Growth Factor

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Obstetrics and Gynecology, Centre Hospitalier Universitaire de Québec-Laval University, Quebec City, Canada. Electronic address: emmanuel.bujold@crchudequebec.ulaval.ca.
  • Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom; Department of Obstetrics and Gynaecology, Monash University, Melbourne, Australia.
  • Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom; Department of Obstetrics and Gynecology, The Chinese University of Hong Kong, Hong Kong.
  • Fetal Medicine Research Institute, King's College Hospital, London, United Kingdom.
  • Institute of Health Research, University of Exeter, Exeter, England, United Kingdom.

Förderung

  • Seventh Framework Programme
  • Fetal Medicine Foundation
  • Quebec Health Research Fund

Zitieren

APA

Bujold, E., Rolnik, D. L., Poon, L., Syngelaki, A., Wright, D., & Nicolaides, K. H. (2026). The effect of aspirin on the risk of preeclampsia based on the Fetal Medicine Foundation first-trimester risk. American Journal of Obstetrics and Gynecology, 234(3), 770-778. https://doi.org/10.1016/j.ajog.2025.10.032

Vancouver

Bujold E, Rolnik DL, Poon L, Syngelaki A, Wright D, Nicolaides KH. The effect of aspirin on the risk of preeclampsia based on the Fetal Medicine Foundation first-trimester risk. American Journal of Obstetrics and Gynecology. 2026;234(3):770-778. doi:10.1016/j.ajog.2025.10.032

BibTeX
@article{Bujold2026,
  author = {Bujold, Emmanuel and Rolnik, Daniel L and Poon, Liona and Syngelaki, Argyro and Wright, David and Nicolaides, Kypros H},
  title = {The effect of aspirin on the risk of preeclampsia based on the Fetal Medicine Foundation first-trimester risk},
  journal = {American Journal of Obstetrics and Gynecology},
  year = {2026},
  volume = {234},
  number = {3},
  pages = {770--778},
  doi = {10.1016/j.ajog.2025.10.032}
}
Kostenlos starten →